Covid-19 roundup: SAB's antibody treatments move to PhIII; After long journey, Novavax submits vaccine to WHO for review
A day after the company lands another $60.5 million to help advance an antibody Covid-19 treatment, SAB Biotherapeutics has announced a positive review from the Data Monitoring Safety Board, and will move into Phase III trials.
Both of the doses tested in a Phase II trial met the pre-trial efficacy goals, the company says, though trial results have not yet been posted to the clinicaltrials.gov website.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.